The multidrug efflux transporter P-glycoprotein (P-gp) is expressed in high concentrations at
the blood–brain barrier (BBB) and is believed to be implicated in resistance to central …

Tariquidar, a potent, nontoxic, third-generation P-glycoprotein (P-gp) inhibitor, is a possible
reversal agent for central nervous system drug resistance. In animal studies, tariquidar has …

Purpose Overactivity of the multidrug efflux transporter P-glycoprotein (P-gp) at the blood-
brain barrier (BBB) is believed to play an important role in resistance to central nervous …

As P-glycoprotein (Pgp) inhibition at the blood–brain barrier (BBB) after administration of a
single dose of tariquidar is transient, we performed positron emission tomography (PET) …

We attempted to assess regional differences in cerebral P-glycoprotein (P-gp) function by
performing paired positron emission tomography (PET) scans with the P-gp substrate (R) …

Using positron emission tomography (PET) imaging we assessed, in vivo, the interaction
between a microdose of (R)‐[11C] verapamil (a P‐glycoprotein (Pgp) substrate) and …

The multiple-drug resistance (MDR) transporter P-glycoprotein (P-gp) is highly expressed at
the human blood–brain barrier (BBB). P-gp actively effluxes a wide variety of drugs from the …

The permeability-glycoprotein (P-gp) efflux transporter is densely expressed at the blood–
brain barrier, and its resultant spare capacity requires substantial blockade to increase the …

Species differences occur in the brain concentrations of drugs, but the reasons for these
differences are not yet apparent. This study was designed to compare brain uptake of three …

Permeability-glycoprotein (P-gp), an efflux transporter in several organs, acts at the blood–
brain barrier to protect the brain from exogenous toxins. P-gp almost completely blocks brain …